Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5932513 | 0.85 | TSHR (0.46) | TSHRALDH1A1CYP2C19 | |
| SCHEMBL25600405 | 0.85 | ACE2 (0.41) | TSHRADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL25007404 | 0.84 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL20079280 | 0.84 | CYP2C19 (0.35) | TSHRADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL19254391 | 0.83 | ADH1B (0.33) | TSHRADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL21610074 | 0.83 | LMNA (0.36) | ADH1BADH1CADH1AALDH1A1CYP1A2 | |
| SCHEMBL25881999 | 0.83 | LMNA (0.39) | TSHRADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL24764379 | 0.83 | LMNA (0.39) | TSHRADH1BADH1CADH1AALDH1A1 | |
| SCHEMBL21754098 | 0.80 | TSHR (0.43) | TSHRCYP1A2CYP2C19 | |
| SCHEMBL20629301 | 0.80 | TSHR (0.43) | TSHRCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540323-B2 | 7-hydroxy-indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259286-A1 | 7-HYDROXY-INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | P2RY1, P2RY11, P2RY2 | TSHR 1205/4885ADH1B 2936/4885ADH1C 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.